Palisade Bio (NASDAQ:PALI) Director Robert Jr. Baltera Buys 20,000 Shares of Stock

Palisade Bio, Inc. (NASDAQ:PALI) Director Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock in a transaction on Wednesday, July 1st. The shares were acquired at an average cost of $1.98 per share, for a total transaction of $39,600.00. Following the completion of the transaction, the director owned 356,904 shares of the company’s stock, valued at $706,669.92. This represents a 5.94% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Robert Jr. Baltera also recently made the following trade(s):

• On Thursday, July 2nd, Robert Jr. Baltera acquired 10,000 shares of Palisade Bio stock. The stock was acquired at an average cost of $1.98 per share, with a total value of $19,800.00.

Palisade Bio Trading Up 3.7%

Shares of NASDAQ PALI opened at $2.12 on Tuesday. Palisade Bio, Inc. has a 12-month low of $0.53 and a 12-month high of $2.86. The company has a market cap of $367.12 million, a P/E ratio of -2.11 and a beta of 1.50. The stock has a fifty day moving average price of $1.91 and a 200 day moving average price of $1.91.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). On average, sell-side analysts forecast that Palisade Bio, Inc. will post -0.25 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a research report on Sunday. HC Wainwright reiterated a “buy” rating and issued a $2.00 price target on shares of Palisade Bio in a research note on Tuesday, June 30th. Wolfe Research started coverage on Palisade Bio in a report on Thursday, April 9th. They issued an “outperform” rating and a $7.00 price objective for the company. Weiss Ratings upgraded Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 29th. Finally, Oppenheimer set a $7.00 target price on Palisade Bio in a report on Tuesday, June 30th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $8.83.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of PALI. CTC Alternative Strategies Ltd. bought a new position in Palisade Bio in the first quarter worth about $31,000. Bank of America Corp DE grew its holdings in shares of Palisade Bio by 181.1% during the first quarter. Bank of America Corp DE now owns 197,074 shares of the company’s stock valued at $345,000 after purchasing an additional 126,977 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Palisade Bio by 1.4% during the 1st quarter. Janus Henderson Group PLC now owns 10,689,452 shares of the company’s stock worth $18,760,000 after purchasing an additional 149,118 shares during the period. ADAR1 Capital Management LLC lifted its holdings in shares of Palisade Bio by 13.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 2,264,845 shares of the company’s stock worth $3,963,000 after purchasing an additional 260,000 shares during the last quarter. Finally, Orbimed Advisors LLC boosted its position in Palisade Bio by 24.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,333,000 shares of the company’s stock valued at $4,083,000 after purchasing an additional 461,580 shares during the period. 11.79% of the stock is currently owned by institutional investors.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.